ArticleUnited European gastroenterology journal2016
Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.
Article in United European gastroenterology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Gene, genetics and genetic medicines in gastroenterology: Current status and its future.World journal of gastroenterology · 2026Review
- Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.Gut · 2025Review
- Diminished immune cell adhesion in hypoimmune ICAM-1 knockout human pluripotent stem cells.Nature communications · 2025Article
- Evolutionarily conserved role of telomerase reverse transcriptase in programming the microenvironment via regulation of the cGAS-STING pathway.Nature cell biology · 2025Article
- Review
- The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
- Emerging therapeutic options in inflammatory bowel disease.World journal of gastroenterology · 2021Review
- Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights.Bioprocess and biosystems engineering · 2021Review
- Medical treatment of pouchitis: a guide for the clinician.Therapeutic advances in gastroenterology · 2021Review
- Review
- Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases.Biologics : targets & therapy · 2020Review
- Targeting immune cell circuits and trafficking in inflammatory bowel disease.Nature immunology · 2019Review
- Novel Non-biologic Targets for Inflammatory Bowel Disease.Current gastroenterology reports · 2019Review
- Vedolizumab for chronic antibiotic-refractory pouchitis.Gastroenterology report · 2019Article
- Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease.Frontiers in pharmacology · 2019Review
- The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.RNA biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe published data about the efficacy of the intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide termed alicaforsen in inflammatory bowel disease (IBD) is rather inconsistent. This case series analyzes its efficacy in chronic refractory pouchitis, after proctocolectomy.
methodsWe performed a retrospective analysis on all patients who had received at least one dose of alicaforsen for IBD at three referral centers in Switzerland. We assessed the drug's efficacy in patients treated for chronic refractory pouchitis, by comparing the clinical and/or endoscopic disease activity at baseline with a 2-3-month follow-up visit.
resultsWe identified 22 patients who had received at least one dose. Among them, 13 patients were being treated for chronic refractory pouchitis. These patients had a median age of 38.0 years (95% CI 21.0-69.0) and five were female (38.5%). The median time since pouch surgery was 102.5 months (95% CI 16.0-288.0), with a median pouchitis duration of 16.0 months (95% CI 4.0-216.0). At 2-3 months after therapy, clinical and endoscopic disease activity was significantly reduced (stool frequency 9.0 versus 6.0, the Pouchitis Disease Activity Index (PDAI) clinical subscore was 4.0 versus 1.0, and the endoscopic disease activity was 4.0 versus 2.0). Clinical improvement was achieved in 11 out of 13 pouchitis patients (84.6%); however, a relapse was observed in nine of these patients (81.8%). The median time from clinical improvement to relapse was 16 weeks (95% CI 9.0-23.0).
conclusionsAlicaforsen seemed to be efficacious in inducing clinical and/or endoscopic improvement in chronic refractory pouchitis and may be a promising treatment alternative in those patients; however, given the high proportion of relapse, one 6-week course of alicaforsen may not be sufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.